LGALS3 and thyroid gland carcinoma: After defining the above issues of the preoperative Gal-3 use, we could have a significant improvement in the management of those patients with indeterminate FNAC reports; in fact, thyroid cancers are not frequent in this class of patients (i.e., up to 25%) and the prognosis of malignant lesions with this preoperative assessment is really good [65,66].